A systematic review of the clinical effectiveness and costeffectiveness of Pharmalgen® for the treatment of bee and wasp venom allergy

Health Technology Assessment

Volumn 16, Issue 12, 2012, Pages

  Hockenhull, J ^a   Elremeli, M ^b   Cherry, M G ^a   Mahon, J ^c   Lai, M ^a   Darroch, J ^d   Oyee, J ^a   Boland, A ^a   Dickson, R ^a   Dundar, Y ^a   Boyle, R ^e  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c Coldingham Economics Consultancy ^*  (United Kingdom)

^d ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^e IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ALUTARD; ANTIHISTAMINIC AGENT; AQUAGEN; BEE VENOM; IMMUNOGLOBULIN E; IMMUNOMODULATING AGENT; PHARMALGEN; UNCLASSIFIED DRUG; WASP VENOM; ALLERGEN; HOUSE DUST ALLERGEN;

ANGIONEUROTIC EDEMA; ANXIETY; AVOIDANCE BEHAVIOR; CLINICAL EFFECTIVENESS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG TOLERABILITY; ECONOMIC EVALUATION; FATALITY; GASTROINTESTINAL DISEASE; HUMAN; IMMUNOTHERAPY; INSECT ALLERGY; MAINTENANCE THERAPY; MORTALITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RESPIRATORY TRACT DISEASE; REVIEW; SELF INJECTION; SHOCK; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; SYSTEMATIC REVIEW; SYSTEMIC DISEASE; THROAT DISEASE; TREATMENT OUTCOME; URTICARIA; ADOLESCENT; ADULT; AGED; ANAPHYLAXIS; DRUG EFFECT; ECONOMICS; FEMALE; MALE; MIDDLE AGED; UNITED KINGDOM; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALLERGENS; ANAPHYLAXIS; ANTIGENS, DERMATOPHAGOIDES; BEE VENOMS; COST-BENEFIT ANALYSIS; FEMALE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; WASP VENOMS; YOUNG ADULT;

EID: 84859199392     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta16120     Document Type: Review

References (131)

1. King T, Lu G, Gonzalez M, Qian N, Soldatova L. Yellow jacket venom allergens, hyaluronidase and phospholipase: sequence similarity and antigenic cross-reactivity with their hornet and wasp homologs and possible implications for clinical allergy. J Allergy Clin Immunol 1996;98:588-600.
2. Lu G, Villalba M, Coscia M, Hoffman D, King T. Sequence analysis and antigenic crossreactivity of a venom allergen, antigen 5, from hornets, wasps, and yellow jackets. J Immunol 1993;150:2823-30.
3. Müller U. New developments in the diagnosis and treatment of hymenoptera venom allergy. Int Arch Allergy Immunol 2001;124:447-53.
4. Fitzgerald K, Flood A. Hymenoptera stings. Clin Tech Small Anim Pract 2006;21:194-204.
5. Bilo MB, Bonifazi F. The natural history and epidemiology of insect venom allergy: clinical implications. Clin Exp Allergy 2009;39:1467-76.
6. Demain J, Minaei A, Tracy J. Anaphylaxis and insect allergy. Curr Opin Allergy Clin Immunol 2010;10:318-22.
7. Freeman T. Hypersensitivity to hymenoptera stings. N Engl J Med 2004;351:1978-84.
8. Mueller UR. Clinical presentation and pathogenesis. In Mueller UR, editor. Insect sting allergy. Stuttgart: Gustav Fischer; 1990. pp. 33-65.
9. Pumphrey R, Stanworth S. The clinical spectrum of anaphylaxis in north-west England. Clin Exp Allergy 1996;26:1364-70.
10. Bilo BM, Bonifazi F. Epidemiology of insect-venom anaphylaxis. Curr Opin Allergy Clin Immunol 2008;8:330-7.
11. Golden DB. Epidemiology of allergy to insect venoms and stings. Allergy Proc 1989;10:103-7.
12. Bilo B, Rueff F, Mosbech H, Bonifazi F, Oude-Elberink J, the EAACI Interest Group on Insect Venom Hypersensitivity. Diagnosis of Hymenoptera venom allergy. Allergy 2005;60:1339-49.
13. Settipane G, Newstead G, Boyd G. Frequency of hymenoptera allergy in an atopic and normal population. J Allergy 1972;50:146-50.
14. Diwakar L, Noorani S, Huissoon AP, Frew AJ, Krishna MT. Practice of venom immunotherapy in the United Kingdom: a national audit and review of literature. Clin Exp Allergy 2008;38:1651-8.
15. The Anaphylaxis Campaign. Allergy to bee and wasp stings. 2005. URL: www.anaphylaxis.org.uk (accessed June 2011).
16. Pumphrey R, Roberts I. Postmortem findings after fatal anaphylactic reactions. J Clin Pathol 2000;53:273-6
17. Pumphrey R. Fatal anaphylaxis in the UK, 1992-2001. In Novartis Foundation, editor. Anaphylaxis. Chichester: Wiley; 2004. pp. 116-28.
18. Golden D, Moffitt J, Nicklas R, Freeman T, Graft D, Reisman R, et al. Stinging insect hypersensitivity: a practice parameter update 2011. J Allergy Clin Immunol 2011;127:852-4.
19. Bilo BM, Bonifazi F. Advances in hymenoptera venom immunotherapy. Curr Opin Allergy Clin Immunol 2007;7:567-73.
20. Adkis C, Blesken T, Akdis M. Role of interleukin 10 in specific immunotherapy. J Clin Invest 1998;102:98.
21. O'Garra A, Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med 2004;10:801-5.
22. Bellinghausen I, Knop J, Saloga J. Role of interleukin 10-producing T cells in specific (allergen) immunotherapy. J Allergy Clin Immunol 2000;12:20-5.
23. Working Group of the Resuscitation Council (UK). Emergency treatment of anaphylactic reactions: guidelines for healthcare providers 2008. URL: www.resus.org.uk/pages/reaction.pdf (accessed June 2011).
24. Müller U, Mosbech H, Aberer W, Dreborg S, Ewan P, Kunkel G, et al. EAACI Position Paper. Adrenaline for emergency kits. Allergy 1995;50:783-7.
25. Soar J, Pumphrey R, Cant A, Clarke S, Corbett A, Dawson P, et al. Emergency treatment of anaphylactic reactions-guidelines for healthcare providers. Resuscitation 2008;77:157-69.
26. Joint Task Force on Practice Parameters, American Academy of Allergy Asthma and Immunology, American College of Allergy, Asthma and Immunology, Joint Council of Allergy, Asthma and Immunology. Allergen immunotherapy: a practice parameter second update. J Allergy Clin Immunol 2007;120(Suppl. 3):25-85.
27. British Society for Allergy and Clinical Immunology. URL: www.bsaci.org/index. php?option=com_clinics&Itemid=26 (accessed June 2011).
28. Hunt KJ, Valentine MD, Sobotka AK, Benton AW, Amodio FJ, Lichtenstein LM. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 1978;299:157-61.
29. Portnoy J, Moffitt J, Golden D, Bernstein W, Dykewicz M, Fineman S, et al. Stinging insect hypersensitivity: a practice parameter. J Allergy Clin Immunol 1999;103:963-80.
30. Moffitt JE, Golden DB, Reisman RE, Lee R, Nicklas R, Freeman T, et al. Stinging insect hypersensitivity: a practice parameter update. J Allergy Clin Immunol 2004;114:869-86.
31. ALK Abelló. Pharmalgen summary of product characteristics. URL: www.alk-abello.com/UK/products/pharma/Lists/Pharmalgen/Pharmalgen%20Wasp %20Venom%20SmPC.pdf (accessed June 2011).
32. Patriarca G, Nucera E, Roncallo C, Aruanno A, Lombardo C, Decinti M, et al. Sublingual desensitization in patients with wasp venom allergy: preliminary results. Int J Immunopathol Pharmacol 2008;21:669-77.
33. Elremeli M, Bulsara Max K, Daniels M, Boyle RJ. Venom immunotherapy for preventing allergic reactions to insect stings. Cochrane Database Syst Rev 2012; in press.
34. Centre for Reviews and Dissemination. Systematic reviews: CRD's guidance for undertaking reviews in healthcare. URL: www.york.ac.uk/inst/crd/darefaq.htm (accessed June 2011).
35. Higgins J, Thompson S. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58.
36. Higgins J, Thompson S, Deeks J, Altman D. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
37. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS-a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput 2000;10:325-37.
38. Multi-parameter Evidence Synthesis Research Group. Formal methods for multi-parameter evidence synthesis and their role in epidemiology and economic evaluation. URL: www.bristol. ac.uk/cobm/research/mpes (accessed June 2011).
39. Brooks SP, Gelman A. Alternative methods for monitoring convergence of iterative simulations. J Comput Graph Stat 1998;7:434-55.
40. Cadario G, Marengo F, Ranghino E, Rossi R, Gatti B, Cantone R, et al. Higher frequency of early local side effects with aqueous versus depot immunotherapy for Hymenoptera venom allergy. J Investig Allergol Clin Immunol 2004;14:127-33.
41. Golden D, Valentine MD, Sobotka AK, Lichtenstein LM. Regimens of hymenoptera venom immunotherapy. J Allergy Clin Immunol 1979;63:180.
42. Golden DBK, Kagey-Sobotka A, Valentine MD, Lichtenstein LM. Prolonged maintenance interval in hymenoptera venom immunotherapy. J Allergy Clin Immunol 1981;67:482-4.
43. Golden DBK, Kagey-Sobotka A, Valentine MD, Lichtenstein LM. Dose dependence of hymenoptera venom immunotherapy. J Allergy Clin Immunol 1981;67:370-4.
44. Golden DBK, Valentine MD, Kagey-Sobotka A, Lichtenstein LM. Regimens of hymenoptera venom immunotherapy. Ann Intern Med 1980;92:620-4.
45. Mosbech H, Malling HJ, Biering I. Immunotherapy with yellow jacket venom. A comparative study including three different extracts, one adsorbed to aluminium hydroxide and two unmodified. Allergy 1986;41:95-103.
46. Müller U, Lanner A, Schmid P, Bischof M, Dreborg S, Hoigné R. A double blind study on immunotherapy with chemically modified honey bee venom: monomethoxy polyethylene glycol-coupled versus crude honey bee venom. Int Arch Allergy Appl Immunol 1985;77:201-3.
47. Müller U, Rabson AR, Bischof M, Lomnitzer R, Dreborg S, Lanner A. A double-blind study comparing monomethoxy polyethylene glycol-modified honeybee venom and unmodified honeybee venom for immunotherapy. I. Clinical results. J Allergy Clin Immunol 1987;80:252-61.
48. Quercia O, Rafanelli S, Puccinelli P, Stefanini GF. The safety of cluster immunotherapy with aluminium hydroxide-adsorbed honey bee venom extract. J Investig Allergol Clin Immunol 2001;11:27-33.
49. Thurnheer U, Müller U, Stoller R. Venom immunotherapy in hymenoptera sting allergy. Comparison of rush and conventional hyposensitization and observations during long-term treatment. Allergy 1983;38:465-75.
50. Mueller HL. Diagnosis and treatment of insect sensitivity. J Asthma Res 1966;3:331-3.
51. Wuthrich B. Classification of sting insect sensitivity. J Investig Allergol Clin Immunol 2001;11:132.
52. Huber PJ. Atopie und Hymenopterenstichallergie. Thesis. Bern: University of Bern; 1981.
53. Lockey RF, Turkeltaub PC, Olive ES, Hubbard JM, Baird-Warren IA, Bukantz SC. The Hymenoptera venom study. III: safety of venom immunotherapy. J Allergy Clin Immunol 1990;86:775-80.
54. Ramirez DA, Londono S, Evans IRD. Adverse reactions to venom immunotherapy. Ann Allergy 1981;47:435-9.
55. Carballada Gonzalez FJ, Crehuet Almirall M, Manjon Herrero A, De la Torre F, Boquete Paris M. Hymenoptera venom allergy: characteristics, tolerance and efficacy of immunotherapy in the paediatric population. Allergol Immunopathol 2009;37:111-15.
56. Graft DF, Schuberth KC, Kagey-Sobotka A. Assessment of prolonged venom immunotherapy in children. J Allergy Clin Immunol 1987;80:162-9.
57. Urbanek R, Forster J, Kuhn W, Ziupa J. Discontinuation of bee venom immunotherapy in children and adolescents. J Pediatr 1985;107:367-71.
58. Carballada F, Boquete M, Nunez R, Lombardero M, de la Torre F. Follow-up of venom immunotherapy (VIT) based on conventional techniques and monitoring of immunoglobulin E to individual venom allergens. J Investig Allergol Clin Immunol 2010;20:506-13.
59. Haeberli G, Bronnimann M, Hunziker T, Müller U. Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. Clin Exp Allergy 2003;33:1216-20.
60. Kochuyt AM, Stevens EAM. Safety and efficacy of a 12-week maintenance interval in patients treated with hymenoptera venom immunotherapy. Clin Exp Allergy 1994;24:35-41.
61. Lerch E, Müller UR. Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients. J Allergy Clin Immunol 1998;101:606-12.
62. Müller UR, Helbling A, Berchtold E. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol 1992;89:529-35.
63. Müller U, Helbling A, Bischof M. Predictive value of venom-specific IgE, IgG and IgG subclass antibodies in patients on immunotherapy with honey bee venom. Allergy 1989;44:412-8.
64. Sanchez-Machin I, Moreno C, Gonzalez R, Iglesias-Souto J, Perez E, Matheu V. Safety of a 2-visit cluster schedule of venom immunotherapy in outpatients at risk of life-threatening anaphylaxis. J Investig Allergol Clin Immunol 2010;20:91-2.
65. Kalogeromitros D, Makris M, Koti I, Chliva C, Mellios A, Avgerinou G, et al. A simple 3-day 'rush' venom immunotherapy protocol: documentation of safety. Allergol Immunopathol 2010;38:69-73.
66. Fricker M, Helbling A, Schwartz L, Müller U. Hymenoptera sting anaphylaxis and urticaria pigmentosa: clinical findings and results of venom immunotherapy in ten patients. J Allergy Clin Immunol 1997;100:11-15.
67. Haugaard L, Norregaard OF, Dahl R. In-hospital sting challenge in insect venom-allergic patients after stopping venom immunotherapy. J Allergy Clin Immunol 1991;87:699-702.
68. Schiavino D, Nucera E, Pollastrini E, De Pasquale T, Buonomo A, Bartolozzi F, et al. Specific ultrarush desensitization in hymenoptera venom-allergic patients. Ann Allergy Asthma Immunol 2004;92:409-13.
69. Szymanski W, Chyrek-Borowska S. Humoral immunological response in patients with venom allergy during specific immunotherapy. Rocz Akad Med Bialymst 1995;40:376-82.
70. Carballada F, Martin S, Boquete M. High efficacy and absence of severe systemic reactions after venom immunotherapy. J Investig Allergol Clin Immunol 2003;13:43-9.
71. Ross RN, Nelson HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of hymenoptera venom hypersensitivity: a meta-analysis. Clin Ther 2000;22:351-8.
72. Watanabe AS, Fonseca LA, Galvao CE, Kalil J, Castro FF. Specific immunotherapy using Hymenoptera venom: systematic review. Sao Paulo Med J 2010;128:30-7.
73. Graft DF, Schuberth KC, Kagey-Sobotka A, Kwiterovich KA, Niv Y, Lichtenstein LM, et al. The development of negative skin tests in children treated with venom immunotherapy. J Allergy Clin Immunol 1984;73:61-8.
74. Müller U, Thurnheer U, Patrizzi R, Spiess J, Hoigne R. Immunotherapy in bee sting hypersensitivity. Bee venom versus wholebody extract. Allergy 1979;34:369-78.
75. Schuberth KC, Lichtenstein LM, Kagey-Sobotka A, Szklo M, Kwiterovich KA, Valentine MD. Epidemiologic study of insect allergy in children. II. Effect of accidental stings in allergic children. J Pediatr 1983;102:361-5.
76. Tsicopoulos A, Tonnel AB, Wallaert B, Joseph M, Ameisen JC, Ramon P, et al. Decrease of IgE-dependent platelet activation in Hymenoptera hypersensitivity after specific rush desensitization. Clin Exp Immunol 1988;71:433-8.
77. Wyss M, Scheitlin T, Stadler BM, Wuthrich B. Immunotherapy with aluminum hydroxide adsorbed insect venom extracts (Alutard SQ): immunologic and clinical results of a prospective study over 3 years. Allergy 1993;48:81-6.
78. Yunginger JW, Paull BR, Jones RT, Santrach PJ. Rush venom immunotherapy program for honeybee sting sensitivity. J Allergy Clin Immunol 1979;63:340-7.
79. Brown SG, Wiese MD, Blackman KE, Heddle RJ. Ant venom immunotherapy: a doubleblind, placebo-controlled, crossover trial. Lancet 2003;361:1001-6.
80. Valentine MD, Schuberth KC, Kagey-Sobotka A, Graft DF, Kwiterovich KA, Szklo M, et al. The value of immunotherapy with venom in children with allergy to insect stings. N Engl J Med 1990;323:1601-3.
81. Golden DBK, Kelly D, Hamilton RG, Craig TJ. Venom immunotherapy reduces large local reactions to insect stings. J Allergy Clin Immunol 2009;123:1371-5.
82. Elberink HO, Monchy JD, Guyatt G, Dubois A. Venom immunotherapy (VIT) improves health-related quality of life (HROL) in patients with allergic reactions following yellowjacket stings-extended observations. J Allergy Clin Immunol 2001;107:S222.
83. Oude Elberink JNG, De Monchy JGR, Van Der Heide S, Guyatt GH, Dubois AEJ. Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom. J Allergy Clin Immunol 2002;110:174-82.
84. Oude Elberink JNG, van der Heide S, Guyatt GH, Dubois AEJ. Analysis of the burden of treatment in patients receiving an EpiPen for yellow jacket anaphylaxis. J Allergy Clin Immunol 2006;118:699-704.
85. Oude Elberink H. Efficacy of yellow jacket immunotherapy during and after stopping venom immunotherapy (VIT) after 1-24 years: followup of 499 patients. Allergy 2009;64:40.
86. Severino MG, Cortellini G, Bonadonna P, Francescato E, Panzini I, Macchia D, et al. Sublingual immunotherapy for large local reactions caused by honeybee sting: a doubleblind, placebo-controlled trial. J Allergy Clin Immunol 2008;122:44-8.
87. Oude Elberink JNG, Van Der Heide S, Guyatt GH, Dubois AEJ. Immunotherapy improves health-related quality of life of adult patients with dermal reactions following yellow jacket stings. Clin Exp Allergy 2009;39:883-9.
88. Song F. Checklist for quality assessment of published reviews. York: NHS Centre for Reviews and Dissemination, University of York; 1994.
89. Oude Elberink J, de Monchy J, Golden D, Brouwer J, Guyatt G, Dubois A. Development and validation of a health-related quality-of-life questionnaire in patients with yellow jacket allergy. J Allergy Clin Immunol 2002;109:162-70.
90. Bernstein JA, Kagen SL, Bernstein DI, Bernstein IL. Rapid venom immunotherapy is safe for routine use in the treatment of patients with Hymenoptera anaphylaxis. Ann Allergy 1994;73:423-8
91. Shaker MS. An economic evaluation of prophylactic self-injectable epinephrine to prevent fatalities in children with mild venom anaphylaxis. Ann Allergy Asthma Immunol 2007;99:424-8.
92. Brown KF, Shaker MS, Jenkins PC, Verdi MS. A cost-effectiveness analysis of venom desensitization in children treated for cure and risk-reduction. J Allergy Clinical Immunol 2006;117:S309.
93. Department of Health. NHS Reference Costs (2009-2010). 2011. URL: www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPoli cyAndGuidance/DH_111591 (accessed June 2011).
94. Curtis L. Unit costs of health and social care 2009. Canterbury: Personal Social Services Research Unit, University of Kent; 2010. URL: www.pssru.ac.uk/uc/uc2009contents.htm (accessed June 2011).
95. British Medical Association and Royal Pharmaceutical Society of Great Britain. British national formulary. No. 61, March 2011. London: BMA and RPS; 2007. URL: www.bnf.org/bnf/(accessed June 2011).
96. Office for National Statistics. Age-specific death rates: by sex, 2001. Regional Trends, No. 38; 2001. URL: www.statistics.gov.uk/STATBASE/ssdataset.asp?vlnk=7673 (accessed June 2011).
97. Bonifazi F, Jutel M, Bilo BM, Birnbaum J, Müller U. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy 2005;60:1459-70.
98. Haye R, Dosen LK. Insect sting allergy. A study from 1980 to 2003 of patients who started treatment with venom immunotherapy between 1980 and 1998. Clin Mol Allergy 2005;3:12.
99. Roesch A, Boerzsoenyi J, Babilas P, Landthaler M, Szeimies RM. [Outcome survey of insect venom allergic patients with venom immunotherapy in a rural population.] J Dtsch Dermatol Ges 2008;6:292-7.
100. Reisman RE. Natural history of insect sting allergy: relationship of severity of symptoms of initial sting anaphylaxis to re-sting reactions. J Allergy Clin Immunol 1992;90:335-9.
101. Sheikh A, Shehata YA, Brown SGA, Simons FER. Adrenaline for the treatment of anaphylaxis: Cochrane systematic review. Denmark: Cochrane Collaboration; 2009. URL: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl &NEWS=N &AN=19178399 (accessed June 2011).
102. Sheikh A, Ten Broek V, Brown SGA, Simons FER. H1-antihistamines for the treatment of anaphylaxis: Cochrane systematic review. Denmark: Cochrane Collaboration; 2007. URL: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl &NEWS=N &AN=17620060 (accessed June 2011).
103. Pumphrey R, Pumphrey R. Anaphylaxis: can we tell who is at risk of a fatal reaction? Curr Opin Allergy Clin Immunol 2004;4:285-90.
104. National Health Service. Hospital episode statistics. 2010. URL: www.hesonline.nhs.uk/Ease/servlet/ContentServer?siteID=1937&category ID=245 (accessed June 2011).
105. Kind P, Hardman G, Macran S. UK population norms for EQ-5D. Discussion Paper 172. York: Centre for Health Economics, University of York; 1999.
106. Alessandrini AE, Berra D, Rizzini FL, Mauro M, Melchiorre A, Rossi F, et al. Flexible approaches in the design of subcutaneous immunotherapy protocols for Hymenoptera venom allergy. Ann Allergy Asthma Immunol 2006;97:92-7.
107. Bilo B, Severino M, Cilia M, Pio A, Casino G, Campodonico P, et al. Safety and tolerability of venom immunotherapy with purified extracts in comparison with nonpurified products. A randomised controlled multicentre trial in 94 patients. Allergy 2009;64:341-2.
108. Bilo MB, Severino M, Cilia M, Pio A, Casino G, Ferrarini E, et al. The VISYT trial: venom immunotherapy safety and tolerability with purified vs nonpurified extracts. Ann Allergy Asthma Immunol 2009;103:57-61.
109. Birnbaum J, Charpin D, Vervloet D. Rapid hymenoptera venom immunotherapy: comparative safety of three protocols. Clin Exp Allergy 1993;23:226-30.
110. Bousquet J, Fontez A, Aznar R. Combination of passive and active immunization in honeybee venom immunotherapy. J Allergy Clin Immunol 1987;79:947-54.
111. Brehler R, Wolf H, Kutting B, Schnitker J, Luger T. Safety of a two-day ultrarush insect venom immunotherapy protocol in comparison with protocols of longer duration and involving a larger number of injections. J Allergy Clin Immunol 2000;105:1231-5.
112. Clayton WF, Reisman RE, Mueller U, Arbesman CE. Modified rapid venom desensitization. Clin Allergy 1983;13:123-9.
113. Glerant JC, Martinez P, Guillaume C, Jounieaux V. Comparison of 2 maintenance doses (100 mug vs 200 mug) in Hymenoptera venom immunotherapy: influence of the maintenance close on the immunologic response. Ann Allergy Asthma Immunol 2005;94:451-6.
114. Hafner T, DuBuske L, Kosnik M. Long-term efficacy of venom immunotherapy. Ann Allergy Asthma Immunol 2008;100:162-5.
115. Kranzelbinder B, Schuster C, Aberer W, Sturm G. Hymenoptera venom immunotherapy: comparison of different updosing regimes regarding side effects and efficacy. Allergy 2009;64:457.
116. Malling HJ, Djurup R, Sondergaard I, Weeke B. Clustered immunotherapy with yellow jacket venom. Evaluation of the influence of time interval on in vivo and in vitro parameters. Allergy 1985;40:373-83.
117. Quercia O, Emiliani F, Pecora S, Burastero SE, Stefanini GF. Efficacy, safety, and modulation of immunologic markers by immunotherapy with honeybee venom: comparison of standardized quality depot versus aqueous extract. Allergy Asthma Proc 2006;27:151-8.
118. Reisman RE, Lantner R. Further observations of stopping venom immunotherapy: comparison of patients stopped because of a fall in serum venom-specific IgE to insignificant levels with patients stopped prematurely by self-choice. J Allergy Clin Immunol 1989;83:1049-54.
119. Reisman RE, Dvorin DJ, Randolph CC, Georgitis JW. Stinging insect allergy: natural history and modification with venom immunotherapy. J Allergy Clin Immunol 1985;75:735-40.
120. Rerinck HC, Przybilla B, Ruff F. Venom immunotherapy (VIT) in patients with systemic mastocytosis (SM) and Hymenoptera venom anaphylaxis (HVA): safety and efficacy of different maintenance doses. J Allergy Clin Immunol 2009;123(Suppl. 2):242.
121. Rueff F, Wolf H, Schnitker J, Ring J, Przybilla B. Specific immunotherapy in honeybee venom allergy: a comparative study using aqueous and aluminium hydroxide adsorbed preparations. Allergy 2004;59:589-95.
122. Golden DB, Kagey-Sobotka A, Norman PS, Hamilton RG, Lichtenstein LM. Outcomes of allergy to insect stings in children, with and without venom immunotherapy. N Engl J Med 2004;351:668-74.
123. Lui CL, Heddle RJ, Kupa A, Coates T, Roberts-Thomas PJ. Bee venom hypersensitivity and its management: patients perception of venom desensitisation. Asian Pac J Allergy 1995;13:95-100.
124. Oude Elberink J. Venom immunotherapy (VIT): clinical efficacy and improvement in quality of life. Drugs Today 2008;44:43-5.
125. Smith PL, Kagey-Sobotka A, Bleecker ER, Traystman R, Kaplan AP, Gralnick H, et al. Physiologic manifestations of human anaphylaxis. J Clin Invest 1980;66:1072-80.
126. Cichocka-Jarosz E, Tobiasz-Adamczyk B, Brzyski P, Lis G, Jedynak U, Pietrzyk J, et al. Health related quality of life (HRQoL) in Polish children treated with specific venom immunotherapy (VIT): a multicenter study. Allergy 2009;64:343.
127. Confino-Cohen R, Melamed S, Goldberg A. Debilitating beliefs, emotional distress and quality of life in patients given immunotherapy for insect sting allergy. Clin Exp Allergy 1999;29:1626-31.
128. Confino-Cohen R, Melamed S, Goldberg A. Debilitating beliefs and emotional distress in patients given immunotherapy for insect sting allergy: a prospective study. Allergy Asthma Proc 2009;30:546-51.
129. Kahan E, Ben-Moshe R, Derazne E, Tamir R. The impact of Hymenoptera venom allergy on occupational activities. Occup Med 1997;47:273-6.
130. Koutsostathis N, Vovolis V, Poulios G, Sifnaios E, Keratsas S, Mikos N. Factors associated to proper technique and carrying compliance with self-injectable adrenaline in insect venom allergic patients and its effect on patients' quality of life. Allergy 2009;64:34-5.
131. Roberts-Thomson PJ, Harvey P, Sperber S, Kupa A, Heddle RJ. Bee sting anaphylaxis in an urban population of South Australia. Asian Pac J Allergy 1985;3:161-4.